| Overview |
| bs-14505R-Cy5 |
| EEFSEC Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Dog, Cow, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human EEFSEC |
| 21-120/596 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 60678 |
| P57772 |
| Cytoplasm, Nucleus |
| EFSEC; SELB_HUMAN_ Elongation factor for selenoprotein translation; Elongation factor sec; Eukaryotic elongation factor, selenocysteine tRNA specific; SELB; Selenocysteine specific elongation factor. |
| EEFSEC is a 596 amino acid protein that localizes to both the nucleus and the cytoplasm and belongs to the GTP-binding elongation factor family. Functioning as a translation factor, SELB binds GTP and GDP and is necessary for the incorporation of selenocysteine into target proteins. The gene encoding SELB maps to human chromosome 3, which houses over 1,100 genes, including a chemokine receptor (CKR) gene cluster and a variety of human cancer-related gene loci. Key tumor suppressing genes on chromosome 3 include those that encode the apoptosis mediator RASSF1, the cell migration regulator HYAL1 and the angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz